# 2022 Health Plan Ratings Required HEDIS<sup>®</sup>, CAHPS<sup>®</sup> and HOS Measures

# **Commercial & Medicaid:**

HEDIS MY 2021 & CAHPS MY 2021 (Reporting Year 2022)

# **Medicare:**

**HEDIS MY 2021 (Reporting Year 2022)** 

**CAHPS MY 2020 (Reporting Year 2021)** 

HOS MY 2020 (Reporting Year 2021)



# 2022 HPR REQUIRED HEDIS, CAHPS AND HOS MEASURES

### **Summary of Changes to Measure List:**

#### July 2021 Posting

· Added the following measures:

	Measure Name	Commercial	Medicare	Medicaid
SAA	Adherence to Antipsychotic Medications for Individuals With Schizophrenia	✓	✓	(currently in HPR)
FUI	Follow-Up After High Intensity Care for Substance Use Disorder (7-Day Rate)	✓	✓	✓
HFS	Hospitalization Following Discharge From a Skilled Nursing Facility (30-Day Rate)		✓	
POD	Pharmacotherapy for Opioid Use Disorder	✓	✓	✓
PCR	Plan All-Cause Readmissions	(add back to HPR scoring for 2022)	(add back to HPR scoring for 2022)	<b>√</b>
PRS-E	Prenatal Immunization Status (Combination Rate)	✓		✓
COU	Risk of Continued Opioid Use—31-day rate	(currently in HPR)	✓	(currently in HPR)

#### July 2022 Posting

- After reviewing the MY 2021 data, the following measures were removed from 2022 HPR scoring due to insufficient data:
  - o Claims Processing (commercial)
  - Rating of Specialist Seen Most Often (Medicaid)
  - Coordination of Care (Medicaid)

#### June 2022 Posting

• Added "potentially risky" to the Display Name for the Risk of Continued Opioid Use (COU) measure.

#### January 2022 Posting

• Added "-E" to the Prenatal Immunization Status (PRS) measure abbreviation to denote the Electronic Clinical Data System (ECDS) reporting method.

#### December 2021 Posting

- Added the COU measure to the Medicare product line in the "Measure Additions" table.
- Removed the footnote about the Emergency Department Utilization (EDU) measure pending public reporting status; EDU will be publicly reported and required for HPR 2022.
- Revised and consolidated the subcomposites for all three product lines.

# **HEDIS/CAHPS Measures Required for HP Accreditation—Commercial**

HEDIS MY 2021 & CAHPS MY 2021 (Reporting Year 2022)

**Note:** The **weight** column indicates the weight of the item (maximum value = 3) in the overall score calculation.

	Measure Name	Display Name	Weight
PATIEN	T EXPERIENCE		•
Getting	Care		
Get	ting Needed Care (Usually + Always)	Getting care easily	1.5
Get	ting Care Quickly (Usually + Always)	Getting care quickly	1.5
Satisfac	tion With Plan Physicians		
Rati	ng of Personal Doctor (9 + 10)	Rating of primary care doctor	1.5
Rati	ng of Specialist Seen Most Often (9 + 10)	Rating of specialists	1.5
Coo	ordination of Care (Usually + Always)	Coordination of care	1.5
Satisfac	tion With Plan and Plan Services		
Rati	ng of Health Plan (9 + 10)	Rating of health plan	1.5
Rati	ng of All Health Care (9 + 10)	Rating of care	1.5
PREVE	NTION		
Children	n and Adolescent Well-Care		
CIS	Childhood Immunization Status—Combination 10	Childhood immunizations	3
IMA	Immunizations for Adolescents—Combination 2	Adolescent immunizations	3
WCC	Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents—BMI Percentile—Total	BMI percentile assessment	1
Women	's Reproductive Health		
PPC	Prenatal and Postpartum Care—Timeliness of Prenatal Care	Prenatal checkups	1
	Prenatal and Postpartum Care—Postpartum Care	Postpartum care	1
PRS-E	Prenatal Immunization Status—Combination Rate	Prenatal immunizations	1
Cancer	Screening		
BCS	Breast Cancer Screening	Breast cancer screening	1
COL	Colorectal Cancer Screening	Colorectal cancer screening	1
CCS	Cervical Cancer Screening	Cervical cancer screening	1
Other P	reventive Services		
CHL	Chlamydia Screening in Women—Total	Chlamydia screening	1
FVA	Flu Vaccinations for Adults Ages 18-64	Flu shots	1
TREATI	MENT		
Respira	tory		
AMR	Asthma Medication Ratio—Total	Asthma control	1
CWP	Appropriate Testing for Pharyngitis—Total	Appropriate testing and care for a sore throat	1
URI	Appropriate Treatment for Upper Respiratory Infection—Total	Appropriate antibiotic use for colds	1

	Measure Name	Display Name	Weight
TREAT	MENT		
AAB	Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis—Total	Appropriate antibiotic use for acute bronchitis/bronchiolitis	1
DOE	Pharmacotherapy Management of COPD Exacerbation—Systemic Corticosteroid	Steroid after hospitalization for acute COPD	1
PCE	Pharmacotherapy Management of COPD Exacerbation—Bronchodilator	Bronchodilator after hospitalization for acute COPD	1
Diabete	es		
	Comprehensive Diabetes Care—Blood Pressure Control (<140/90)	Blood pressure control (140/90)	3
CDC	Comprehensive Diabetes Care—Eye Exams	Eye exams	1
	Comprehensive Diabetes Care—HbA1c Control (<8%)	Glucose control	3
CDD	Statin Therapy for Patients With Diabetes— Received Statin Therapy	Patients with diabetes—received statin therapy	1
SPD	Statin Therapy for Patients With Diabetes— Statin Adherence 80%	Patients with diabetes—statin adherence 80%	1
Heart D	Disease		
000	Statin Therapy for Patients With Cardiovascular Disease—Received Statin Therapy—Total	Patients with cardiovascular disease—received statin therapy	1
SPC	Statin Therapy for Patients With Cardiovascular Disease—Statin Adherence 80%—Total	Patients with cardiovascular disease—statin adherence 80%	1
CBP	Controlling High Blood Pressure	Controlling high blood pressure	3
Behavi	oral Health—Care Coordination		
FUH	Follow-Up After Hospitalization for Mental Illness— 7 days—Total	Follow-up after hospitalization for mental illness	1
FUM	Follow-Up After Emergency Department Visit for Mental Illness—7 days—Total	Follow-up after ED for mental illness	1
FUA	Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence—7 days—Total	Follow-up after ED for alcohol and other drug abuse or dependence	1
FUI	Follow-Up After High-Intensity Care for Substance Use Disorder—7 days—Total	Follow-up after high-intensity care for substance use disorder	1
Behavi	oral Health—Medication Adherence		
SAA	Adherence to Antipsychotic Medications for Individuals With Schizophrenia	Adherence to antipsychotic medications for individuals with schizophrenia	1
AMM	Antidepressant Medication Management—Effective Continuation Phase Treatment	Patients with a new episode of depression—medication adherence for 6 months	1
POD	Pharmacotherapy for Opioid Use Disorder—Total	Patients with opioid use disorder—medication adherence for 6 months	1
Behavi	oral Health—Access, Monitoring and Safety		
APM	Metabolic Monitoring for Children and Adolescents on Antipsychotics—Blood Glucose and Cholesterol Testing—Total	Cholesterol and blood sugar testing for youth on antipsychotic medications	1

	Measure Name	Display Name	Weight
APP	Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics—Total	First-line psychosocial care for youth on antipsychotic medications	1
ADD	Follow-Up Care for Children Prescribed ADHD Medication—Continuation & Maintenance Phase	Continued follow-up after ADHD diagnosis	1
IET	Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment—Engagement of AOD Treatment—Total	Alcohol or drug abuse or dependence treatment engaged	1
Risk-A	Adjusted Utilization		
AHU	Acute Hospital Utilization—Observed-to-Expected Ratio—Total Acute—Total	Acute hospital utilization	1
PCR	Plan All-Cause Readmissions—Observed-to- Expected Ratio—18-64 years	Plan all-cause readmissions	1
EDU	Emergency Department Utilization—Observed-to- Expected Ratio—Total	Emergency department utilization	1
Overu	se of Opioids		
HDO	Use of Opioids at High Dosage	Avoiding opioids at high dosage	1
UOP	Use of Opioids from Multiple Providers—Multiple Prescribers and Multiple Pharmacies	Avoiding opioids from multiple prescribers and multiple pharmacies	1
COU	Risk of Continued Opioid Use—31-day rate—Total	Avoiding potentially risky continued opioid use	1
Other	Treatment Measures		
LBP	Use of Imaging Studies for Low Back Pain	Appropriate use of imaging studies for low back pain	1

### HEDIS/CAHPS/HOS Measures Required for HP Accreditation—Medicare

HEDIS MY 2021 (Reporting Year 2022); CAHPS MY 2020 (Reporting Year 2021); HOS MY 2020 (Reporting Year 2021)

**Note:** The weight column indicates the weight of the item (maximum value = 3) in the overall score calculation.

Veight
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1
1
1
1
1
1
3
1
3
1
1

	Measure Name	Display Name	Weight
TREAT	MENT		
Heart D	Disease		
SPC	Statin Therapy for Patients With Cardiovascular Disease—Received Statin Therapy—Total	Patients with cardiovascular disease—received statin therapy	1
350	Statin Therapy for Patients With Cardiovascular Disease—Statin Adherence 80%—Total	Patients with cardiovascular disease—statin adherence 80%	1
CBP	Controlling High Blood Pressure	Controlling high blood pressure	3
Behavi	oral Health—Care Coordination		
FUH	Follow-Up After Hospitalization for Mental Illness—7 days—Total	Follow-up after hospitalization for mental illness	1
FUM	Follow-Up After Emergency Department Visit for Mental Illness—7 days—Total	Follow-up after ED for mental illness	1
FUA	Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence—7 days—Total	Follow-up after ED for alcohol and other drug abuse or dependence	1
FUI	Follow-Up After High-Intensity Care for Substance Use Disorder—7 days—Total	Follow-up after high-intensity care for substance use disorder	1
Behavi	oral Health—Medication Adherence		
SAA	Adherence to Antipsychotic Medications for Individuals With Schizophrenia	Adherence to antipsychotic medications for individuals with schizophrenia	1
POD	Pharmacotherapy for Opioid Use Disorder—Total	Patients with opioid use disorder—medication adherence for 6 months	1
AMM	Antidepressant Medication Management—Effective Continuation Phase Treatment	Patients with a new episode of depression—medication adherence for 6 months	1
Behavi	oral Health—Access, Monitoring and Safety		
IET	Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment—Engagement of AOD Treatment—Total	Alcohol or drug abuse or dependence treatment engaged	1
Patient	Safety and Treatment for Older Adults		
PSA	Non-Recommended PSA-Based Screening in Older Men	Avoiding non-recommended prostate cancer screening in older men	1
DDE	Potentially Harmful Drug Disease Interactions in Older Adults—Total	Avoiding potentially harmful drug and disease interactions in older adults	1
DAE	Use of High-Risk Medications in Older Adults— High-Risk Medications to Avoid	Avoiding high-risk medications for older adults	1
FRM	Fall Risk Management	Managing risk of falls	1
OMW	Osteoporosis Management in Women Who Had a Fracture	Managing osteoporosis in women after fracture	1

	Measure Name	Display Name	Weight
TREA	<b>TMENT</b>		
Care C	Coordination		
FMC	Follow-Up After Emergency Department Visit for People With Multiple High-Risk Chronic Conditions—65+ years	Follow-up after ED for multiple high- risk chronic conditions	1
	Transitions of Care—Notification of Inpatient Admission—65+ years	Transitions of Care—notification of inpatient admission	1
TRC	Transitions of Care—Receipt of Discharge Information—65+ years	Transitions of Care—receipt of discharge information	1
IKC	Transitions of Care—Patient Engagement After Inpatient Discharge—65+ years	Transitions of Care—patient engagement after inpatient discharge	1
	Transitions of Care—Medication Reconciliation Post-Discharge—65+ years	Transitions of Care—medication reconciliation post-discharge	1
Risk-A	Adjusted Utilization		
PCR	Plan All-Cause Readmissions—Observed-to-Expected Ratio—65+ years	Plan all-cause readmissions	1
EDU	Emergency Department Utilization—Observed-to- Expected Ratio—65+ years	Emergency department utilization	1
AHU	Acute Hospital Utilization—Observed-to-Expected Ratio—Total Acute—65+ years	Acute hospital utilization	1
HPC	Hospitalization for Potentially Preventable Complications—Total ACSC—Observed-to-Expected Ratio—Total	Hospitalization for potentially preventable complications	1
HFS	Hospitalization Following Discharge From a Skilled Nursing Facility—30-Day—Total	Hospitalization following SNF discharge	1
Overu	se of Opioids		
HDO	Use of Opioids at High Dosage	Avoiding opioids at high dosage	1
UOP	Use of Opioids from Multiple Providers—Multiple Prescribers and Multiple Pharmacies	Avoiding opioids from multiple prescribers and multiple pharmacies	1
COU	Risk of Continued Opioid Use—31-day rate—Total	Avoiding potentially risky continued opioid use	1

# **HEDIS/CAHPS Measures Required for HP Accreditation—Medicaid**

HEDIS MY 2021 & CAHPS MY 2021 (Reporting Year 2022)

**Note:** The **weight** column indicates the weight of the item (maximum value = 3) in the overall score calculation.

	Measure Name	Display Name	Weight		
PATIEN	PATIENT EXPERIENCE				
Getting	Care				
Get	ting Needed Care (Usually + Always)	Getting care easily	1.5		
Get	ting Care Quickly (Usually + Always)	Getting care quickly	1.5		
Satisfac	tion With Plan Physicians				
Rati	ng of Personal Doctor (9 + 10)	Rating of primary care doctor	1.5		
Satisfac	tion With Plan and Plan Services				
Rati	ng of Health Plan (9 + 10)	Rating of health plan	1.5		
Rati	ng of All Health Care (9 + 10)	Rating of care	1.5		
PREVEN	NTION				
Children	and Adolescent Well-Care				
ADV	Annual Dental Visit—Total	Dental visits	1		
CIS	Childhood Immunization Status—Combination 10	Childhood immunizations	3		
IMA	Immunizations for Adolescents—Combination 2	Adolescent immunizations	3		
WCC	Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents—BMI Percentile—Total	BMI percentile assessment	1		
Women	's Reproductive Health		•		
PPC	Prenatal and Postpartum Care—Timeliness of Prenatal Care	Prenatal checkups	1		
	Prenatal and Postpartum Care—Postpartum Care	Postpartum care	1		
PRS-E	Prenatal Immunization Status —Combination Rate	Prenatal immunizations	1		
Cancer	Screening				
BCS	Breast Cancer Screening	Breast cancer screening	1		
CCS	Cervical Cancer Screening	Cervical cancer screening	1		
Other P	reventive Services				
CHL	Chlamydia Screening in Women—Total	Chlamydia screening	1		
FVA	Flu Vaccinations for Adults Ages 18-64	Flu shots	1		
MSC	Medical Assistance With Smoking and Tobacco Use Cessation—Advising Smokers and Tobacco Users to Quit	Smoking advice	1		

	Measure Name	Display Name	Weight
TREAT	MENT		
Respira	atory		
AMR	Asthma Medication Ratio—Total	Asthma control	1
CWP	Appropriate Testing for Pharyngitis—Total	Appropriate testing and care for a sore throat	1
URI	Appropriate Treatment for Upper Respiratory Infection—Total	Appropriate antibiotic use for colds	1
AAB	Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis—Total	Appropriate antibiotic use for acute bronchitis/bronchiolitis	1
PCE	Pharmacotherapy Management of COPD Exacerbation—Systemic Corticosteroid	Steroid after hospitalization for acute COPD	1
PUE	Pharmacotherapy Management of COPD Exacerbation—Bronchodilator	Bronchodilator after hospitalization for acute COPD	1
Diabete	es		
	Comprehensive Diabetes Care—Blood Pressure Control (<140/90)	Blood pressure control (140/90)	3
CDC	Comprehensive Diabetes Care—Eye Exams	Eye exams	1
	Comprehensive Diabetes Care—HbA1c Control (<8%)	Glucose control	3
SPD	Statin Therapy for Patients With Diabetes— Received Statin Therapy	Patients with diabetes—received statin therapy	1
SPD	Statin Therapy for Patients With Diabetes— Statin Adherence 80%	Patients with diabetes—statin adherence 80%	1
Heart D	Disease		
SPC	Statin Therapy for Patients With Cardiovascular Disease—Received Statin Therapy—Total	Patients with cardiovascular disease— received statin therapy	1
SPC	Statin Therapy for Patients With Cardiovascular Disease—Statin Adherence 80%—Total	Patients with cardiovascular disease— statin adherence 80%	1
CBP	Controlling High Blood Pressure	Controlling high blood pressure	3
Behavi	oral Health—Care Coordination		
FUH	Follow-Up After Hospitalization for Mental Illness—7 days	Follow-up after hospitalization for mental illness	1
FUM	Follow-Up After Emergency Department Visit for Mental Illness—7 days—Total	Follow-up after ED for mental illness	1
FUA	Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence—7 days—Total	Follow-up after ED for alcohol and other drug abuse or dependence	1
FUI	Follow-Up After High-Intensity Care for Substance Use Disorder—7 days—Total	Follow-up after high-intensity care for substance use disorder	1

	Measure Name	Display Name	Weight		
Behavi	Behavioral Health—Medication Adherence				
SAA	Adherence to Antipsychotic Medications for Individuals With Schizophrenia	Adherence to antipsychotic medications for individuals with schizophrenia	1		
AMM	Antidepressant Medication Management— Effective Continuation Phase Treatment	Patients with a new episode of depression—medication adherence for 6 months	1		
POD	Pharmacotherapy for Opioid Use Disorder—Total	Patients with opioid use disorder—medication adherence for 6 months	1		
Behavi	oral Health—Access, Monitoring and Safety				
APM	Metabolic Monitoring for Children and Adolescents on Antipsychotics—Blood Glucose and Cholesterol Testing—Total	Cholesterol and blood sugar testing for youth on antipsychotic medications	1		
ADD	Follow-Up Care for Children Prescribed ADHD Medication—Continuation & Maintenance Phase	Continued follow-up after ADHD diagnosis	1		
SSD	Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications	Diabetes screening for individuals with schizophrenia or bipolar disorder	1		
APP	Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics—Total	First-line psychosocial care for youth on antipsychotic medications	1		
IET	Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment—Engagement of AOD Treatment—Total	Alcohol or drug abuse or dependence treatment engaged	1		
Risk-A	djusted Utilization				
PCR	Plan All-Cause Readmissions—Observed-to- Expected Ratio—18-64 years	Plan all-cause readmissions	1		
Overus	se of Opioids				
HDO	Use of Opioids at High Dosage	Avoiding opioids at high dosage	1		
UOP	Use of Opioids from Multiple Providers—Multiple Prescribers and Multiple Pharmacies	Avoiding opioids from multiple prescribers and multiple pharmacies	1		
COU	Risk of Continued Opioid Use—31-day rate—Total	Avoiding potentially risky continued opioid use	1		
Other 7	Freatment Measures				
LBP	Use of Imaging Studies for Low Back Pain	Appropriate use of imaging studies for low back pain	1		

HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA). CAHPS® is a registered trademark of the Agency for Healthcare Research and Quality (AHRQ).